Global Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others) – Industry Trends and Forecast to 2031.
Fibrotic Diseases Treatment Market Analysis and Size
The fibrotic diseases treatment market witnesses ongoing advancements, providing renewed hope and benefits for patients seeking improved therapies. Innovative therapies, from targeted drugs to regenerative medicine, are transforming treatment approaches. These advancements promise improved outcomes, symptom management, and quality of life for those affected by fibrotic conditions, marking a significant stride forward in medical care.
The global fibrotic diseases treatment market size was valued at USD 3.62 billion in 2023, is projected to reach USD 5.56 billion by 2031, with a CAGR of 5.5% during the forecast period 2024 to 2031. This indicates that the market value. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016 – 2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Genentech, Inc. (U.S.), C.H. Boehringer Ingelheim International GmbH (Germany), AbbVie Inc. (U.S.), Redx Pharma Plc (U.K.), Bristol-Myers Squibb Company (U.S.), BellBrook Labs (U.S.), Enveda (U.S.), BioMX (U.S.), Gilead Sciences, Inc. (U.S.), KITHER BIOTECH S.R.L. (Italy), Verona Pharma plc (U.K.), Alpine Immune Sciences (U.S.),Intercept Pharmaceuticals, Inc. (U.S.), Pharmaxis Ltd (Australia), Teva Pharmaceutical Industries Ltd. (Israel), Sandoz International GmbH (Germany), Accord Healthcare (U.K.), and Camber Pharmaceuticals, Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Fibrotic disease treatment often involves managing symptoms and targeting underlying causes to slow or halt tissue scarring. Therapies may include medication to reduce inflammation and fibrosis progression, lifestyle changes to promote lung or organ health, and, in severe cases, organ transplantation. Research into novel therapies such as targeted molecular agents continue to expand treatment options.
Fibrotic Diseases Treatment Market Dynamics
Drivers
- Rising Prevalence of Fibrotic Diseases
The escalating prevalence of fibrotic diseases, spurred by factors such as aging and obesity, poses a growing socio-economic challenge worldwide. This trend propels the demand for treatments, driving market growth. For instance, the increasing incidence of idiopathic pulmonary fibrosis (IPF) has led to heightened demand for medications such as pirfenidone and nintedanib, driving expansion in the pulmonary fibrosis treatment market.
- Increase in the Number of People Smoking Cigarettes
The rise in cigarette smoking is exacerbating health issues such as Idiopathic Pulmonary Fibrosis (IPF). Research indicates smoking worsens IPF prognosis due to toxic chemicals such as reactive oxygen and nitrogen species (RONS) in cigarette smoke, causing inflammation and fibrosis. This trend underscores the need for advanced treatments, potentially boosting the market for IPF therapies and smoking cessation products.
Opportunities
- Rising Research and Development Activities
Increasing research and development efforts in fibrotic disease medications offer lucrative market growth opportunities. Improving current treatments, such as enhancing anti-fibrotic drugs such as pirfenidone and nintedanib, show considerable potential for advancement. This includes addressing fibrotic lung diseases treatment effectively, meeting evolving consumer preferences, and advancing therapeutic outcomes in the field.
- Development of New and More Effective Therapies
The limited treatment options for fibrotic diseases, such as pirfenidone and nintedanib, oxygen therapy, and transplantation, highlight a crucial need for innovation. The emergence of novel and more efficient therapies, such as gene editing techniques targeting fibrosis pathways, presents significant market opportunities. For instance, the development of anti-fibrotic drugs with enhanced efficacy and fewer side effects can revolutionize fibrotic disease management.
Restraints/Challenges
- High Cost of Medication and Treatments
The escalating prevalence of fibrotic diseases and the rising prices of medications and medical devices are driving up treatment costs. Advanced technological devices, though enhancing treatment accuracy, also contribute to elevated expenses. The resultant high costs are anticipated to impede market growth, posing challenges for patients seeking affordable fibrosis treatments.
- Lack of Effective Biomarkers and Diagnostic Tools
Limited access to chest imaging and reliable lung function tests in developing countries hampers the diagnosis and treatment of conditions such as Idiopathic Pulmonary Fibrosis (IPF). This lack of effective biomarkers and diagnostic tools, exacerbated by challenges in rural healthcare access, restrains market growth by hindering accurate disease assessment and treatment provision in underserved regions.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In May 2023, Boehringer Ingelheim initiated Phase 1 study (NCT05658107) for BI 765423, an IL-11 inhibitor antibody, evaluating safety, tolerability, and pharmacokinetics in healthy volunteers. Pre-clinical findings suggest the potential reversal of fibrosis in various fibrotic diseases
- In May 2023, FDA approved Investigational New Drug Application (IND) for a Phase II study on Idiopathic Pulmonary Fibrosis by Cumberland Pharmaceuticals Inc., targeting the most common progressive fibrosing interstitial lung disease
- In May 2022, Boehringer Ingelheim's BRASS, a digital innovation acquired by ArisGlobal, integrated into LifeSphere as LifeSphere Clarity, enhancing pharmacovigilance and patient safety efforts, expanding clinical diagnostics business globally
- In March 2022, Bristol Myers Squibb acquired Turning Point Therapeutics for USD 76.00 per share, strengthening its global market presence. Unanimously approved by both companies' Boards of Directors, the merger is anticipated to close in Q3 2022, facilitating industry-wide advancement
Fibrotic Diseases Treatment Market Scope
The market is segmented on the basis of treatment, application, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Medication
- Organ Transplantation
- Oxygen Therapy
- Others
Application
- Idiopathic Pulmonary Fibrosis
- Hepatic Cirrhosis
- Renal Fibrosis
- Cutaneous Fibrosis
- Others
End User
- Hospitals
- Specialty Clinics
- Academic and Research Institutes
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Fibrotic Diseases Treatment Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, treatment, application, end user, and distribution channel as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
Asia-Pacific is expected to show the highest growth in the market, propelled by escalating technological advancements in developing regions. This surge fosters enhanced accessibility to innovative therapies, addressing unmet medical needs and driving improved patient outcomes across the region.
North America is poised to lead the market, buoyed by a growing elderly population. High incidences of fibrotic diseases and the presence of key market players further propel market growth in the region, shaping a robust landscape for therapeutic advancements and innovations.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Fibrotic Diseases Treatment Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Genentech, Inc. (U.S.)
- C.H. Boehringer Ingelheim International GmbH (Germany)
- AbbVie Inc. (U.S.)
- Redx Pharma Plc (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- BellBrook Labs (U.S.)
- Enveda (U.S.)
- BioMX (U.S.)
- Gilead Sciences, Inc. (U.S.)
- KITHER BIOTECH S.R.L. (Italy)
- Verona Pharma plc (U.K.)
- Alpine Immune Sciences (U.S.)
- Intercept Pharmaceuticals, Inc. (U.S.)
- Pharmaxis Ltd (Australia)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sandoz International GmbH (Germany)
- Accord Healthcare (U.K.)
- Camber Pharmaceuticals, Inc. (U.S.)
SKU-